Hint mode is switched on Switch off
For swift navigation between sections

Whitehawk Therapeutics
LEI 549300G3U7TKW1M58L09

PDF download

Choose all Reset all
Download Cancel
Organization name
Whitehawk Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Whitehawk Therapeutics, Inc. is a developer of albumin-bound drugs designed to realize the full potential of mTOR inhibition by highly efficient target suppression in mTOR-driven diseases and biomarker-driven patient populations. The company is engaged in developing drugs that help in high tumour penetration due to mechanisms of albumin uptake in tumours and other areas with tissue remodelling or inflammation, enabling patients to block the activity of a protein called mTOR, which is known to be overactive in PEComa cancer cells.

Awards

News

21/05/2026 Whitehawk Therapeutics: Other Events, Financial Statements And Exhibits
12/05/2026 Whitehawk Therapeutics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Financial Statements And Exhibits
30/06/2025 Metaplanet Boosts Bitcoin Holdings to 13,350 BTC, Surpasses Galaxy Digital
11/06/2025 Whitehawk Therapeutics: Submission Of Matters To A Vote Of Security Holders
08/05/2025 Whitehawk Therapeutics: Results Of Operations And Financial Condition, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300G3U7TKW1M58L09
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001422142
  • EIN
    61-1547850
Registration is required to get access.